Importance of prostatic sonography in the evaluation of conservative therapy of prostatic hyperplasia.
Drug therapy using an alpha-reductase inhibitor is being conducted in 23 patients with benign prostatic hyperplasia (BPH), hopefully resulting in a decrease in prostatic volume. Suprapubic ultrasonography determination of prostatic size has proven to be a reliable parameter of the disease course. In 142 evaluated ultrasonic measurements, a maximum deviation of +/- 7% for the diameter and +/- 13% for the volume was established. Therefore a change in volume after drug therapy of BPH can only be considered significant if a decrease in volume is 15% or more.